Proof of Concept: Socket Seal

NCT ID: NCT03063775

Last Updated: 2019-05-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

1 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-01-09

Study Completion Date

2018-11-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It is planned to evaluate if a porcine collagen matrix (Mucograft Seal) is offering comparable results to free gingival grafts (FGG) in post-extraction tissue preservation. If so, this would provide a substantial benefit to the patient as the second intervention on the palate and the subsequent morbidity of the donor site is omitted.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In a proof of concept 5 groups are compared in preserving soft- and hard tissue after tooth extraction in the esthetic zone:

1. Mucograft® Seal + Bio-Oss®
2. Free Gingival Graft (FGG) + Bio-Oss®
3. Free Gingival Graft + Gelatine sponge (Spongostan®)
4. Spongostan®+ Mucograft® Seal
5. Spongostan®

Volumetric changes of hard and soft tissues are recorded , 2/4/8 weeks and 3/6/12 months after extraction.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tissue Preservation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1. Mucograft® Seal + Bio-Oss®

Group Type ACTIVE_COMPARATOR

BioOss® + Mucograft Seal®

Intervention Type DEVICE

Placement of BioOss®-Collagen into the extraction socket. The Mucograft Seal® Membrane is then applied to the socket.

2. FGG + Bio-Oss®

Group Type ACTIVE_COMPARATOR

FGG + Bio-Oss®

Intervention Type OTHER

Placement of BioOss®-Collagen into the extraction socket. The FGG is then attached to the socket.

3. FGG + Gelatine sponge (Spongostan®)

Group Type ACTIVE_COMPARATOR

FGG + Gelatine sponge (Spongostan®)

Intervention Type OTHER

Placement of a Gelatine sponge into the extraction socket, then attaching the FGG to the socket.

4. Spongostan®+ Mucograft® Seal

Group Type ACTIVE_COMPARATOR

Spongostan®+ Mucograft® Seal

Intervention Type DEVICE

Placement of a Gelatine sponge into the extraction socket, then attaching the Mucograft® Seal Membrane to the socket

5. Spongostan®

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BioOss® + Mucograft Seal®

Placement of BioOss®-Collagen into the extraction socket. The Mucograft Seal® Membrane is then applied to the socket.

Intervention Type DEVICE

FGG + Bio-Oss®

Placement of BioOss®-Collagen into the extraction socket. The FGG is then attached to the socket.

Intervention Type OTHER

FGG + Gelatine sponge (Spongostan®)

Placement of a Gelatine sponge into the extraction socket, then attaching the FGG to the socket.

Intervention Type OTHER

Spongostan®+ Mucograft® Seal

Placement of a Gelatine sponge into the extraction socket, then attaching the Mucograft® Seal Membrane to the socket

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

• Planned extraction in the upper front or premolar region

Exclusion Criteria

* General risk situation (antiresorptive therapy, antiangiogenic therapy, history of local radiation therapy, heavy coagulation disorder, relevant allergies, dysregulated Diabetes mellitus, malignant diseases)
* Acute gingivitis
* Deep pockets (\>5.5mm)
* Apical periodontitis on neighboring teeth
* Heavy smoker (\>10/d)
Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medical University of Graz

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medical University Graz

Graz, Styria, Austria

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

7333

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.